Ameriprise
CSTL icon

Ameriprise’s Castle Biosciences CSTL Stock Holding History

Ameriprise’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,368
Closed -$1.38M – 4099
2025
Q4 		$1.38M Sell
35,368
-220,865
-86% -$7.12M ﹤0.01% 3193
2025
Q3 		$5.83M Sell
256,233
-116,234
-31% -$2.36M ﹤0.01% 2325
2025
Q2 		$7.61M Buy
372,467
+46,770
+14% +$866K ﹤0.01% 2024
2025
Q1 		$6.52M Buy
325,697
+9,661
+3% +$239K ﹤0.01% 2104
2024
Q4 		$8.42M Sell
316,036
-33,193
-10% -$1.01M ﹤0.01% 1932
2024
Q3 		$9.96M Buy
349,229
+55,207
+19% +$1.41M ﹤0.01% 1807
2024
Q2 		$6.4M Sell
294,022
-1,305
-0.4% -$29.1K ﹤0.01% 2113
2024
Q1 		$6.54M Buy
295,327
+15,600
+6% +$339K ﹤0.01% 2156
2023
Q4 		$6.04M Buy
279,727
+13,727
+5% +$242K ﹤0.01% 2209
2023
Q3 		$4.49M Sell
266,000
-51,954
-16% -$909K ﹤0.01% 2359
2023
Q2 		$4.36M Buy
317,954
+203,045
+177% +$4.11M ﹤0.01% 2446
2023
Q1 		$2.61M Buy
114,909
+3,670
+3% +$89.7K ﹤0.01% 2709
2022
Q4 		$2.62M Sell
111,239
-21,281
-16% -$493K ﹤0.01% 2691
2022
Q3 		$3.46M Sell
132,520
-27,634
-17% -$775K ﹤0.01% 2487
2022
Q2 		$3.52M Buy
160,154
+36,586
+30% +$850K ﹤0.01% 2523
2022
Q1 		$5.54M Buy
123,568
+14,247
+13% +$589K ﹤0.01% 2355
2021
Q4 		$4.69M Buy
109,321
+17,034
+18% +$890K ﹤0.01% 2506
2021
Q3 		$6.14M Sell
92,287
-1,005
-1% -$70.7K ﹤0.01% 2249
2021
Q2 		$6.84M Sell
93,292
-15,760
-14% -$1.04M ﹤0.01% 2228
2021
Q1 		$7.47M Sell
109,052
-24,950
-19% -$1.88M ﹤0.01% 2107
2020
Q4 		$9M Sell
134,002
-11,914
-8% -$646K ﹤0.01% 1830
2020
Q3 		$7.51M Buy
145,916
+46,923
+47% +$2.09M ﹤0.01% 1776
2020
Q2 		$3.73M Buy
98,993
+60,993
+161% +$2.08M ﹤0.01% 2267
2020
Q1 		$1.13M Buy
+38,000
New +$1.15M ﹤0.01% 2764

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise's CSTL Position: Q1 2026 in Review

Ameriprise sold out of Castle Biosciences (CSTL) in Q1 2026, closing a stake of 35,368 shares — an estimated $1.38M sold.

Ameriprise first reported a position in CSTL in Q1 2020 and held it in 24 quarters. The position peaked at $9.96M in Q3 2024. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Ameriprise reported no remaining Castle Biosciences position as of Q1 2026 after selling out during the quarter.
  • Ameriprise sold 35,368 Castle Biosciences shares in Q1 2026, an estimated $1.38M.
  • Ameriprise first reported a position in Castle Biosciences in Q1 2020 and held it in 24 quarters.
  • Ameriprise's Castle Biosciences position peaked at $9.96M in Q3 2024.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.